This company listing is no longer active
Concert Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-45.4%
Tasa de crecimiento de los beneficios
-40.8%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | -14.6% |
Tasa de crecimiento de los ingresos | 47.4% |
Rentabilidad financiera | -94.8% |
Margen neto | -395.4% |
Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Concert Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 22 | 32 | -127 | 22 | 0 |
30 Jun 22 | 33 | -125 | 22 | 0 |
31 Mar 22 | 33 | -95 | 23 | 0 |
31 Dec 21 | 33 | -80 | 23 | 0 |
30 Sep 21 | 1 | -66 | 22 | 0 |
30 Jun 21 | 2 | -59 | 21 | 0 |
31 Mar 21 | 8 | -77 | 20 | 0 |
31 Dec 20 | 8 | -75 | 19 | 0 |
30 Sep 20 | 8 | -73 | 19 | 0 |
30 Jun 20 | 6 | -71 | 19 | 0 |
31 Mar 20 | 0 | -77 | 19 | 0 |
31 Dec 19 | 1 | -78 | 20 | 0 |
30 Sep 19 | 1 | -79 | 21 | 0 |
30 Jun 19 | 1 | -79 | 22 | 0 |
31 Mar 19 | 1 | -73 | 23 | 0 |
31 Dec 18 | 11 | -56 | 23 | 0 |
30 Sep 18 | 11 | -41 | 23 | 0 |
30 Jun 18 | 11 | 104 | 21 | 0 |
31 Mar 18 | 11 | 104 | 21 | 0 |
31 Dec 17 | 0 | 95 | 21 | 0 |
30 Sep 17 | 0 | 89 | 19 | 0 |
30 Jun 17 | 0 | -50 | 18 | 0 |
31 Mar 17 | 0 | -50 | 16 | 0 |
31 Dec 16 | 0 | -51 | 14 | 0 |
30 Sep 16 | 10 | -38 | 14 | 0 |
30 Jun 16 | 12 | -35 | 14 | 0 |
31 Mar 16 | 15 | 19 | 13 | 0 |
Ingresos de calidad: 73C is currently unprofitable.
Margen de beneficios creciente: 73C is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 73C is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Acelerando crecimiento: Unable to compare 73C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 73C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Rentabilidad financiera
Alta ROE: 73C has a negative Return on Equity (-94.78%), as it is currently unprofitable.